Prevention of meningococcal disease during the Hajj and Umrah mass gatherings: past and current measures and future prospects  by Yezli, Saber et al.
International Journal of Infectious Diseases 47 (2016) 71–78Prevention of meningococcal disease during the Hajj and Umrah mass
gatherings: past and current measures and future prospects
Saber Yezli a,*, Abdulaziz A. Bin Saeed a,b, Abdullah M. Assiri c, Rafat F. Alhakeem c,
Muslim A. Yunus d, Abdulhaﬁz M. Turkistani e, Robert Booy f, Badriah M. Alotaibi a
a The Global Centre for Mass Gatherings Medicine, Public Health Directorate, Ministry of Health, Riyadh, Saudi Arabia
bDepartment of Family and Community Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia
c Public Health Directorate, Ministry of Health, Riyadh, Saudi Arabia
d Immunization Unit, Public Health Directorate, Ministry of Health, Riyadh, Saudi Arabia
eMakkah Regional Health Affairs, Ministry of Health, Jeddah, Saudi Arabia
fNational Centre for Immunisation Research and Surveillance (NCIRS), The Children’s Hospital at Westmead and University of Sydney, Sydney, Australia
A R T I C L E I N F O
Article history:
Received 25 November 2015
Accepted 10 December 2015
Corresponding Editor: Eskild Petersen,
Aarhus, Denmark
Keywords:
Meningococcal disease
Hajj
Mass gathering
Prevention
Meningitis
Vaccine
S U M M A R Y
The Kingdom of Saudi Arabia (KSA) has a long history of instituting preventative measures against
meningococcal disease (MD). KSA is at risk of outbreaks of MD due to its geographic location, demography,
and especially because it hosts the annual Hajj and Umrah mass gatherings. Preventative measures for Hajj
and Umrah include vaccination, targeted chemoprophylaxis, health awareness and educational campaigns,
as well as an active disease surveillance and response system. Preventative measures have been introduced
and updated in accordance with changes in the epidemiology of MD and available preventative tools. The
mandatory meningococcal vaccination policy for pilgrims has possibly been the major factor in preventing
outbreaks during the pilgrimages. The policy of chemoprophylaxis for all pilgrims arriving from the African
meningitis belt has also probably been important in reducing the carriage and transmission of Neisseria
meningitidis in KSA and beyond. The preventative measures for Hajj and Umrah are likely to continue to
focus on vaccination, but to favour the conjugate vaccine for its extra beneﬁts over the polysaccharide
vaccines. Additionally, the surveillance system will continue to be strengthened to ensure early detection
and response to cases and outbreaks; ongoing disease awareness campaigns for pilgrims will continue, as
will chemoprophylaxis for target groups. Local and worldwide surveillance of the disease and drug-
resistant N. meningitidis are crucial in informing future recommendations for vaccination, chemoprophy-
laxis, and treatment. Preventative measures should be reviewed regularly and updated accordingly, and
compliance with these measures should be monitored and enhanced to prevent MD during Hajj and Umrah,
as well as local and international outbreaks.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Meningococcal disease (MD) refers to the spectrum of dangerous
infections caused by Neisseria meningitidis, including meningitis,
bacteraemia, and pneumonia. The rapidity of the disease and
difﬁculty distinguishing it from other febrile infections may result in
delayed diagnosis with high morbidity and mortality.1 Thirteen
serogroups of N. meningitidis have been reported, but only six
serogroups (A, B, C, W135, X, and Y) are responsible for the great
majority of invasive disease worldwide.2 Due to the seriousness of
MD, its disabling sequelae, and the potential for epidemic spread, a* Corresponding author. Tel.: +96611401555 ext. 1863.
E-mail address: saber.yezli@gmail.com (S. Yezli).
http://dx.doi.org/10.1016/j.ijid.2015.12.010
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).single case of MD elicits an urgent public health response. This is
particularly important during global events with a risk for
international spread. The Hajj and Umrah religious mass gatherings
in the Kingdom of Saudi Arabia (KSA) are a case in point. These events
annually draw millions of Muslims from over 180 different countries
to the holy cities of Mecca and Medina for the pilgrimages. The
prevention of MD during Hajj and Umrah is of the utmost
importance for global health security, yet it is extremely challenging
given the large numbers of pilgrims participating, the different
disease epidemiology proﬁles in their countries of origin, and the
crowded conditions during these events. Hajj and Umrah promote
the acquisition of meningococcal carriage and also disease
transmission, and have historically been linked to a number of
local and international meningococcal outbreaks.3,4ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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introduced over the years and have been updated and modiﬁed in
accordance with changes in the epidemiology of the disease and
available data and preventative tools (Figure 1). Supporting these
preventative measures is a well-established and long-standing
disease surveillance system in KSA to characterize MD epidemiol-
ogy (dating back to 1970). It includes a standard clinical case
deﬁnition, ﬁeld investigation of cases and outbreaks, tracing of
contacts, and laboratory capacity for the conﬁrmation and
characterization of N. meningitidis, as recommended by the World
Health Organization (WHO).5 In KSA, the Public Health Depart-
ment, within the Ministry of Health, runs the surveillance system
for rapid reporting of suspected meningitis cases in each of the
20 Health Affairs directorates, with detailed case-reporting
required for all conﬁrmed cases. Laboratory conﬁrmation depends
on either isolation of the causative organism, from cerebrospinal
ﬂuid (CSF) or by blood culture, or by detection of antigen in a
normally sterile site such as the CSF.6 This surveillance system is
enhanced during each Hajj, especially where pilgrims reside or
visit, to include in addition to the standard case reporting, active
case ﬁnding and tracing of contacts for prompt management and
control and real-time updates on suspected or conﬁrmed cases.
The carriage of N. meningitidis among pilgrims and their
contacts and MD and outbreaks during the Hajj and Umrah mass
gatherings have been reviewed previously.3,4 In this review, the
preventative measures implemented by the Saudi health authori-
ties to prevent MD during these events are examined, highlighting
the past and current strategies and forecasting possible future
changes.
2. Prevention of meningococcal disease
In the absence of a vaccine that protects against all serogroups
of N. meningitidis, MD preventative measures are multifactorial and
rely on effective disease surveillance and response, the rapid
generation of reliable epidemiological data, and the implementa-
tion of appropriate vaccination policies, chemoprophylaxis for at-
risk groups, and focussed educational and awareness campaigns.
Vaccination is the most effective way of preventing MD. The WHO
recommends that countries with either intermediate–high en-
demic disease rates (2 cases/100 000 population/year) or
frequent epidemics (irrespective of endemicity) should introduce
appropriate large-scale meningococcal vaccination programmes.
In countries where the disease occurs less frequently (<2 cases/
100 000 population/year), meningococcal vaccination is recom-
mended for groups at high risk of meningococcal exposure and
disease, including travellers to high-endemic areas.5
The ideal meningococcal vaccine would be affordable and
effective against all serogroups of meningococci, would elicit long-
lasting immunity in all age groups, especially infants, children, and
adolescents, and importantly, would provide signiﬁcant herd
immunity.2 Unfortunately, although attempts at vaccine develop-
ment go as far back as the early 1900s,7 and licensed vaccines have
been available since the 1970s, no such vaccine yet exists.5,7
Currently available meningococcal vaccines include polysaccha-
ride and polysaccharide–protein conjugate vaccines; both are
available against meningococci of serogroups A, C, W135, and Y.8
Internationally marketed meningococcal polysaccharide vac-
cines are based on puriﬁed, heat-stable, lyophilized capsular
polysaccharides derived from meningococci of the respective
serogroup and include bivalent (A,C), trivalent (A, C, W135), and
quadrivalent (A, C, W135,Y) formulations.7,8 Licensed meningo-
coccal conjugate vaccines are based on conjugation of poly-
saccharides to protein carriers.7 They include monovalent (A or C)
and quadrivalent (A, C, W135,Y) vaccines, and also a combination
vaccine based on Haemophilus inﬂuenzae type b and N. meningitidisserogroup C (HibMenC).8,9 The ﬁrst quadrivalent (A/C/W/Y)
meningococcal conjugate vaccine was licensed in 2005 and more
have been licensed since.5,7,8
The development of vaccines for broad protection against
serogroup B disease has presented challenges because the native B
polysaccharide potentially cross-reacts with human antigens and
is poorly immunogenic; in addition, other potential antigen targets
of group B meningococci are highly diverse.5,10 B vaccines have
been developed using outer membrane vesicles (OMVs) prepared
from speciﬁc (clonal) outbreak B strains,7 and have been
successfully deployed to control epidemics in Norway, Cuba,
New Zealand, and France.7,10 The OMV vaccines are immunogenic,
but require multiple doses, especially in infants, and appear to
induce protection of relatively short duration.7 Efforts to ﬁnd novel
vaccine antigens to protect against serogroup B disease have led to
a number of vaccine candidates that are currently under
investigation in clinical trials.7,10 Two of these vaccines are
licensed in a few countries and recommended for certain risk
groups and have been used to control outbreaks.11,12 No vaccine is
available against disease caused by serogroup X meningococci.5
Polysaccharide vaccines are essentially T-cell independent
antigens, hence they are weakly immunogenic (especially in
infants), induce a poor immunological memory response, and
provide a relatively short duration of protection.7,9 Polysaccharide
vaccines do not reliably reduce the carriage rate, nor do they
prevent the spread of meningococci by asymptomatic carriers.5,13
In addition, they cannot be boosted; in fact, repeated polysaccha-
ride vaccinations can result in a reduced immune response (hypo-
responsiveness).5,9,13 The conjugate vaccines are more immuno-
genic and induce immunological memory.9 Repeated doses with
quadrivalent meningococcal conjugate vaccines do not result in
hypo-responsiveness but show a clear booster effect. They have the
potential to reduce the carrier rate and hence may contribute to the
reduction of N. meningitidis transmission.7,8
Various meningococcal vaccines are used in different countries
depending on the national epidemiology, socioeconomic
resources, licensing laws, and national recommendations.5,8 Due
to the high cost of conjugate vaccines, the WHO endorses the use of
polysaccharide vaccines in mass vaccinations to control outbreaks
in countries with limited economic resources or an insufﬁcient
supply of meningococcal conjugate vaccines. However, due to the
limited efﬁcacy of polysaccharide vaccines in children <2 years of
age, in conﬁrmed group A or C outbreaks the appropriate
monovalent conjugate serogroup A and C vaccines should be used
for protection of those aged 12–24 months and 2–24 months,
respectively.5
Chemoprophylaxis for at-risk individuals is also a key compo-
nent of MD prevention. Close contacts of cases are at risk of
secondary disease. Antibiotics are effective in preventing addi-
tional cases through eradicating carriage of the invasive strain so
that transmission is prevented. Antibiotic chemoprophylaxis is
used to prevent disease in close contacts of cases and can be offered
to at-risk individuals during outbreaks.5Mass chemoprophylaxis is
also used in target populations on arrival to Saudi Arabia for the
Hajj and Umrah pilgrimages.14 Ciproﬂoxacin, ceftriaxone, rifampi-
cin, and azithromycin are all effective for chemoprophylaxis,5,15,16
but ciproﬂoxacin is the agent of choice because it can be used as a
single dose and lacks toxicity.17
3. Hajj and Umrah meningococcal disease preventative
measures: past and current policies and compliance
3.1. Past strategies
Meningococcal vaccines have been available in KSA since the
1970s, and until 1987, vaccination against MD was only required
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Figure 1. Timeline for meningococcal disease preventative measures for the Hajj and Umrah mass gatherings.
S. Yezli et al. / International Journal of Infectious Diseases 47 (2016) 71–78 73
S. Yezli et al. / International Journal of Infectious Diseases 47 (2016) 71–7874for Hajj visas for pilgrims from the Sub-Saharan African
countries.18 In that year, the ﬁrst reported international outbreak
following the Hajj occurred caused by N. meningitidis serogroup A
belonging to the III-1 clonal complex.19 The disease spread rapidly
among pilgrims and also the indigenous Saudi population, and was
exported internationally via colonized pilgrims returning
home.19,20 A study by the US Centers for Disease Control and
Prevention (CDC) investigated passengers returning from Saudi
Arabia in 1987 and found that pilgrims were signiﬁcantly more
likely to be carriers of serogroup A meningococcus than were non-
pilgrims.21 Primarily on the basis of these data, the CDC began
recommending vaccination against MD for all travellers to the
Hajj.22 The CDC recommended the then licensed quadrivalent A/C/
W/Y meningococcal polysaccharide vaccine.23
The attack rate of the 1987 outbreak was lowest among
pilgrims from the meningitis belt of Sub-Saharan Africa who had
been required to be vaccinated against MD before their arrival in
Mecca.9 However, the high attack rates in pilgrims from other
countries prompted the Saudi authorities to extend the visa
requirement for mandatory meningococcal vaccination to all Hajj
pilgrims worldwide. Beginning in 1988, the bivalent A/C menin-
gococcal polysaccharide vaccine became mandatory for all
pilgrims entering KSA. All Hajj visitors were required to produce
a certiﬁcate of vaccination issued not more than 3 years and not
less than 10 days before entering the Kingdom. Pilgrims from
countries where MD was endemic were screened; suspect disease
cases would be isolated and contacts put under observation. In
addition, Hajj workers were also vaccinated and the Saudi health
authorities launched campaigns of public education and offered
free vaccine to all residents living in the holy cities of Mecca and
Medina and their neighbouring areas.18 This was coupled with the
compulsory administration of oral ciproﬂoxacin to pilgrims
coming from the Sub-Saharan African meningitis belt, in an
attempt to reduce the carriage rate.24 The mass chemoprophylaxis
policy for these target countries has been in effect since.
Consequently, a marked decrease in the number of meningococ-
cal-related illnesses was observed, and the measures seemed to
control the epidemic MD during the following few years.4
In 1991, following the Gulf conﬂict, unprecedented numbers of
pilgrims came for Umrah. This prompted the Saudi health
authorities to extend the meningococcal vaccination requirement
to all Umrah visas 2 months before the 1992 lunar month of
Ramadan.18 During the same period, two outbreaks of MD
occurred among residents and Umrah visitors in Mecca and
Jeddah.18,25 The implicated strain was serogroup A N. meningitidis
of the same clonal complex that caused the 1987 outbreak.19 Cases
were mainly among people who had not received the vaccine. The
most common reason mentioned for not being vaccinated was lack
of knowledge about the disease.18,25 Although these outbreaks
were not known to have spread beyond Saudi Arabia,18 educational
campaigns were introduced and mass vaccination with the
bivalent A/C polysaccharide vaccine was implemented in both
Mecca and Jeddah, which quelled the outbreaks.18,24,25
By 1996, the Saudi health recommendations for international
visitors for Hajj and Umrah and seasonal work remained focused
on vaccination with the bivalent A/C vaccine received no more than
3 years and no less than 10 days before arrival in the Kingdom
(single dose for adults and children over 2 years of age and two
doses of the monovalent A vaccine for children between 3 months
and 2 years of age with a 3-month interval). Additionally, arrivals
from the African meningitis belt were, as before, administered
chemoprophylaxis. Visitors from these countries could be checked
at entry points and suspected cases isolated and preventative
measures taken in respect to their contacts. If the authenticity of
the vaccination certiﬁcation was felt to be questionable, revacci-
nation was to be carried out.26In 1997 during the month of Ramadan in the Umrah season, an
increase in the number of cases of serogroup A disease was noted
with over 70% of the cases being religious visitors.27,28 In response,
ciproﬂoxacin chemoprophylaxis was given to all household
contacts of a conﬁrmed or suspected case and a vaccination
programme with the bivalent A/C vaccine was initiated. In addition
the monovalent A vaccine was temporarily incorporated into the
routine Saudi childhood vaccination programme for children aged
3 months to 2 years.9 These measures reduced the cases of MD in
the Kingdom and in 1999 there was no evidence of epidemic MD in
the country. Because of this, the CDC revised its earlier
recommendations for meningococcal vaccination for those travel-
ling to Saudi Arabia and advised that vaccination was no longer
required.29 The Saudi health recommendations for the prevention
of MD for visitors to the Kingdom remained, however, unchanged
until the early 2000s.30
In 2000 and 2001, two major Hajj-related international
meningococcal outbreaks occurred caused by serogroup W135,
previously considered a minor subgroup of little clinical impor-
tance.27,31,32 Shortly after the 2000 Hajj, over 400 W135 disease
cases were reported in Hajj pilgrims and their close contacts from
16 countries, with a high case fatality rate.27,31 Attempts by the
local health authorities to make the quadrivalent A/C/W/Y
polysaccharide vaccine available for the 2000 Hajj season were
unsuccessful because of a shortage of vaccine supply.24 The
2000 outbreak was followed by another smaller outbreak in
2001.32 To assess the risk for MD in 2001 among US pilgrims, the
CDC conducted a study of pharyngeal carriage of N. meningitidis in
pilgrims before and after the Hajj.33 The study found that carriage
of serogroup W135 was similar among pilgrims and non-pilgrims
(0.8% vs. 0.9%; p = 0.98). On the basis of the low rate of carriage in
the study population, prophylactic antibiotics were not recom-
mended for returning Hajjis.33 However, to minimize the risk, the
Saudi health authorities recommended ciproﬂoxacin prophylaxis
for local pilgrims at the end of Hajj before returning to their
families in order to eliminate carriage.34,35
The sudden change in the epidemiology of MD in the 2000 Hajj
prompted enhanced surveillance in many countries to monitor the
spread and virulence of the W135 outbreak strain and to collect data
on case characteristics.27,31,35–37 It also meant that the quadrivalent
vaccine became the vaccine of choice for those performing the Hajj
instead of the bivalent formulation.24 However, despite this change,
the quadrivalent vaccine coverage was only partial in pilgrims from
many countries in the 2001 Hajj due to the late availability of the
vaccine prior to the pilgrimage.36,37
By 2002, the quadrivalent A/C/W/Y polysaccharide meningo-
coccal vaccine was a visa requirement for Hajj and Umrah and all
international health authorities were ofﬁcially notiﬁed of this
change.38 In addition to vaccination of all national and interna-
tional pilgrims, the Saudi authorities introduced a vaccination
programme for children and adults living in Mecca and Medina,
healthcare workers in the Kingdom, and government personnel
serving the pilgrims.39 The quadrivalent vaccination campaign for
children initially targeted children aged between 6 month and
5 years, but later changed to only children over 2 years of age due
to the poor immunogenicity of the serogroups C, Y, and W135
polysaccharides in younger children.9,40 The strict implementation
of these measures was associated with the absence of outbreaks
related to N. meningitidis W135 in 2002, and no pilgrimage-
associated outbreaks have been reported in KSA since.39
As of 2007, the prevention policy recommended the quadriva-
lent vaccine to all national and international pilgrims, residents
of the holy cities, Hajj workers, and those working at entry points
to the Kingdom or in direct contact with pilgrims. The recom-
mendations no longer speciﬁed the polysaccharide vaccine, as
the conjugate quadrivalent vaccine was also licensed by then. In
S. Yezli et al. / International Journal of Infectious Diseases 47 (2016) 71–78 75addition, chemoprophylaxis (1 tablet of 500 mg ciproﬂoxacin for
adults, rifampicin for children, and ceftriaxone for pregnant
women) was to be administered to pilgrims arriving from the
African meningitis belt, but no longer for pilgrims leaving the Hajj
premises.13,41
At the meeting of the Gulf Cooperation Council (GCC) States
Meningitis Study Group held in 2009 in Riyadh, Saudi Arabia, there
was a consensus that going forward, comprehensive vaccination
with the conjugate quadrivalent vaccine would be recommended
for all GCC states pilgrims, as they can afford the increased cost
associated with the vaccine. The vaccine would also be advisable
for all other countries. One year later, in Dubai, UAE, a meeting of
experts from 11 countries in the Middle East region at a
Meningococcal Leadership Forum agreed that in general, the
conjugate vaccine should replace plain polysaccharide vaccines,
starting with high-risk groups (primarily pilgrims) and continuing
down during a transition period in which both vaccines would be
available. For pilgrims at least it should be ensured that everyone
coming for Hajj or Umrah is vaccinated against A, C, W, and Y
meningococci, prioritizing conjugate vaccines as early as availa-
ble.13
Since 2010, a conjugated quadrivalent A/C/W/Y meningococcal
vaccine has been given to the same target groups in Saudi Arabia
aged from >2 to 55 years. The vaccines are administered during
annual vaccination campaigns in Mecca and Medina in a single
dose, with boosters every 3 years.13 In 2013, the Kingdom
introduced the conjugate quadrivalent ACWY vaccine into the
routine childhood vaccination programme. However, despite the
potential beneﬁts of the conjugate vaccine, the high cost has
prohibited the Saudi Arabian Ministry of Health from making it a
mandatory vaccine for all international pilgrims.6,13
3.2. Current recommendations
The current (2015) recommendations for MD prevention in Hajj
and Umrah have changed little from those in 2007, requiring
vaccination with the quadrivalent vaccine for the same target
groups and additional ciproﬂoxacin chemoprophylaxis for adults
and children over the age of 12 years arriving from the African
meningitis belt.42 In the Kingdom, the quadrivalent conjugate
vaccine is used for persons aged from 9 months to 55 years. The
polysaccharide quadrivalent vaccine is still used for those older
than 55 years, as per the licensing of the vaccine.8 While the
conjugate quadrivalent vaccine is used routinely in a number of
countries, due to cost and availability issues, many other countries,Table 1
Reported meningococcal vaccination coverage among Hajj pilgrims
Study population Study year Vaccine coverage
USAa 1987 17% of travellers 
8 countries 2001 Some pilgrims 
USA 2001 >97% of pilgrims
Thailand 2001 77.8% of pilgrims
Singapore 2001 100% of pilgrims 
Singapore 2002 100% of pilgrims 
UK 2002 100% of pilgrims 
29 countries 2003 >44% of pilgrims
Iran 2003 100% of pilgrims 
Iran 2003 100% of pilgrims 
Kuwait 2005 92% of pilgrims 
UK 2006 100% of pilgrims 
KSA 2006 64% of pilgrims 
Turkey 2010 100% of pilgrims 
Iran 2012 100% of pilgrims 
22 countries 2013 100% of pilgrims 
a High-risk travellers (including pilgrims and non-pilgrims) who visited Mecca and especially in low-income areas, continue to use the polysaccharide
vaccine.5,8
3.3. Compliance with preventative measures
Strict adherence to the MD preventative measures is crucial for
these measures to be effective. It is reasonable to assume that the
mass chemoprophylaxis measures at point of entry are well
adhered to despite the challenges in implementing these
measures, including the refusal of some pilgrims to take the
prophylactic antibiotic.43 This is because ciproﬂoxacin is system-
atically administered upon arrival to KSA by the Saudi health
authorities to all pilgrims originating from the African meningitis
belt. In the 2015 Hajj, chemoprophylaxis was administered to
99.1% of the target population (unpublished data). However,
compliance may not be as high for other pilgrims and locals when
mass chemoprophylaxis is offered during outbreaks. Data on the
compliance with mass chemoprophylaxis preventative measures
over the years in KSA are lacking.
A number of studies have reported the rate of compliance with
the meningococcal vaccination recommendations among pilgrims
and locals (Table 1). The reported rates have varied depending on
the population investigated and the study year. Studies conducted
among small cohorts of international pilgrims from speciﬁc
nationalities have reported a vaccination coverage rate of over
90% during or after the 2001 outbreak. Other studies conducted on
multiple nationalities have documented both high and low
rates.35,44,45 Currently, the entry requirement that is enforced
through border checks suggests that compliance with meningo-
coccal vaccination recommendations among international pil-
grims is high. For instance, a recent study investigated over
5000 international pilgrims from 22 countries during the 2013 Hajj.
According to their vaccination documents, all pilgrims had
received meningococcal vaccination.45 The limitation of the
reported data was that they were based only on vaccination
documents and not on actual immunological proﬁles of pilgrims.
Using serology, Memish et al. assessed the immunological
proﬁle of 741 international pilgrims on arrival to KSA against the
four meningococcal serogroups contained within the compulsory
quadrivalent vaccine.46 The pilgrims originated from 15 countries
including low-, medium-, and high-incidence countries. Antibo-
dies in blood samples from pilgrims were quantiﬁed by serum
bactericidal antibody assay using baby rabbit complement against
the four meningococcal serogroups, A, C, W, and Y. The results
showed that the vast majority of pilgrims were vaccinated, with Vaccine type Ref.
Meningococcal vaccine unspeciﬁed 21
Meningococcal vaccine unspeciﬁed 44
 Quadrivalent polysaccharide vaccine 64
 Meningococcal vaccine unspeciﬁed 65
Quadrivalent polysaccharide vaccine 54
Quadrivalent polysaccharide vaccine 66
Quadrivalent polysaccharide vaccine 52
 Quadrivalent vaccine (92%)
Bivalent vaccine (8%)
35
Quadrivalent polysaccharide vaccine 16
Quadrivalent polysaccharide vaccine 16
Quadrivalent vaccine 56
Meningococcal vaccine unspeciﬁed 48
Meningococcal vaccine unspeciﬁed 48
Quadrivalent polysaccharide vaccine 51
Quadrivalent polysaccharide vaccine 67
Meningococcal vaccine unspeciﬁed 45
Medina during the Hajj season.
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vaccine in the last 3 years. Of the 13 who had not, all originated
from Bangladesh, with four reporting no previous meningococcal
vaccination and nine reporting having received the vaccination
more than 3 years ago. In the 2015 Hajj, overall vaccine coverage
among international pilgrims arriving in KSA was 91%, however
few countries had coverage less than 70% (unpublished data).
These unvaccinated pilgrims are given antibiotic chemoprophy-
laxis.
While compliance with vaccination appears to be high among
international pilgrims, compliance among Saudi pilgrims may be
poorer. This is because Mecca residents do not have to provide
proof of vaccination, and legislation regarding other Saudi citizens
is not always enforced. Admittedly, targeted vaccination of Hajj
pilgrims and Mecca and Medina residents in Saudi Arabia has
improved vaccine coverage. For instance, in Mecca the coverage
rate increased from 1.3% in 1990–1991 to 12% in 1991–1992 and
reached 73% in 1992–1993.18,47 However, overall it appears that
vaccine coverage is not adequate among Saudi pilgrims. In 2006, a
study of 134 British and 109 Saudi Hajj pilgrims reported that
vaccine coverage was lower among local residents (64%) than
among British pilgrims (100%).48 According to the study question-
naire, 50% of local pilgrims residing in Mecca and Jeddah had been
vaccinated, compared with 71% from the rest of the country. The
authors concluded that the lower vaccine coverage in Saudi
pilgrims overall, and the native residents of Mecca in particular, is
worrying and could lead to further meningococcal outbreaks.48
Vaccination among healthcare workers (HCWs) is also of
importance. Meningococcal vaccination is required for HCWs
working in Hajj locations and those with contact with pilgrims.
Few studies have investigated vaccine coverage among HCWs
working in Hajj locations. In general, these have reported
suboptimal coverage.49,50 In one study conducted in 2003, among
the 392 HCWs working in Mecca (both resident and recruited from
other regions of the Kingdom), 323 (82.4%) had received the
recommended quadrivalent meningococcal vaccine.49 Of those
who had received the vaccine, 52 (16.1%) had received it within
less than 2 weeks, which was not in compliance with the Ministry
of Health recommendations. Currently, the stricter measures for
compliance with the vaccination policy for HCWs during Hajj,
including checks of vaccination documents, suggest that compli-
ance nowadays is high.
4. Hajj and Umrah meningococcal disease preventative
measures: future prospects
4.1. Vaccination
Vaccination will continue to be the cornerstone of the MD
preventative measures during Hajj and Umrah. A progressive move
towards the use of the quadrivalent conjugate vaccine for all
pilgrims has been proposed,6 and if the vaccine becomes cheaper
and more available, low-income countries will join many others
countries in using the conjugate vaccine to immunize their
pilgrims. In the meantime, the conjugate vaccines may still be cost-
effective in the long-term if their effect on herd immunity is taken
into account.5 Polysaccharide vaccines are likely to be used less
because of their drawbacks, including a decreasing immune
response with repeated doses. This hypo-responsiveness is an
important issue, especially for those who often perform Hajj and
Umrah and are vaccinated every 1–3 years.13
Due to the possibility of a rapid change in the epidemiology
of MD during Hajj and Umrah, contingency plans should be in place
to contain outbreaks. For instance outbreaks due to serogroup B are
concerning and could occur. Serogroup B N. meningitidis is regularly
isolated from asymptomatic Hajj and Umrah pilgrims,16,51,52 andmany countries with large Muslim populations have been
experiencing an increasing trend of serogroup B MD.53 New
serogroup B vaccines are available, and although there are some
unresolved scientiﬁc and social issues surrounding these vaccines,12
the Saudi health authorities may consider the use of these vaccines
in the case of future outbreaks, as has been done in other countries.11
Such contingency measures should be in place, including ensuring
the availability of the vaccines if needed.
The meningococcal vaccination policy for Hajj and Umrah will
continue to be updated based on the availability of vaccines and
will be informed by the epidemiology of the disease. An available
and cheap vaccine that protects against most/all invasive disease-
causing serogroups, with a good safety and immunity proﬁle in all
ages, which also impacts carriage and reduces transmission, will be
the ideal vaccine to prevent the disease in Hajj and Umrah. Such a
vaccine would signiﬁcantly reduce the cases of MD at these mass
gatherings, provide effective and long-lasting protection, and
would probably end the current mass chemoprophylaxis policy.
4.2. Antibiotic chemoprophylaxis
Chemoprophylaxis should continue to be part of MD preventa-
tive measures for high-risk groups such as close contacts of cases.
Mass chemoprophylaxis for pilgrims not in contact with cases,
however, remains controversial, with some supporting its imple-
mentation,16,48,54 while others voice concerns over the practice,
especially among certain populations.35,55 From one perspective,
chemoprophylaxis can reduce or eliminate the carriage of
N. meningitidis, therefore reducing the risk of transmission and
disease.16,56 This is particularly important for pilgrims arriving
from the African meningitis belt and all returning pilgrims after
Hajj. This is the more relevant given that vaccines currently used
by many pilgrims do not have a major impact on carriage and their
uptake is variable, especially among locals.48 Travellers from the
African meningitis belt with a potentially high carriage rate could
disseminate the organism among pilgrims and the local popula-
tion. Also, returning pilgrims carrying N. meningitidis after Hajj
or Umrah have been shown to represent a sizeable reservoir of
transmissible and persistent clones, which places their unvacci-
nated family contacts, and potentially the community at large, at
risk of invasive disease.54,57
On the other hand, the increasing use of conjugate vaccines,
which should prevent the acquisition of carriage and reduce
transmission, plus concerns over the effectiveness, cost, and long-
term effect on antibiotic resistance in N. meningitidis and many
other microbes, renders the mass chemoprophylaxis policy
unattractive. Even though antibiotic resistance in N. meningitidis
is uncommon, resistance or reduced susceptibility to agents used
for the treatment and chemoprophylaxis of patients with MD and
their contacts have been reported.15,17,58 Concerns over the
development of antibiotic resistance are justiﬁed because of the
severity of the disease caused by the organism and the need for
immediate treatment of infected patients. Effective chemopro-
phylaxis is also crucial for close contact of cases to prevent
secondary cases and reduce morbidity and mortality.
Ciproﬂoxacin resistance has been reported from around the
world, including North America, France, Spain, Australia, Argentina,
and India.15,17 In addition, the importation of resistance to other
countries has been documented. For instance, Lapadula et al.
reported the importation of ciproﬂoxacin-resistant N. meningitidis to
Italy via a traveller who visited India.58 The isolate was of the same
sequence type as the ciproﬂoxacin-resistant N. meningitidis ser-
ogroup A that caused outbreaks in India in 2005 and 2006.17
Annually, thousands of pilgrims visit Saudi Arabia from India for Hajj
and Umrah, in addition to a large resident workforce from the
country. It is plausible that similar importation of resistant strains
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their countries of origin after the pilgrimages. At the 2009 Hajj, the
prevalence of N. meningitidis resistance to antibiotics used for
prophylaxis, i.e., ciproﬂoxacin, ceftriaxone, rifampicin, and azithro-
mycin, was 5%, 12%, 3%, and 9%, respectively.59 The clinical
signiﬁcance of the emergence of resistance in N. meningitidis to
agents used for chemoprophylaxis is still unclear; however it may
lead to failure in protecting at-risk individuals and the development
of invasive disease.15
4.3. Health awareness, education, and training
Health education and awareness on MD symptoms and
preventative measures should continue for local pilgrims, resi-
dents of the holy cities, and Hajj workers. Knowledge about the
disease and key symptoms and signs has been shown to be
associated with high meningococcal vaccine uptake among
travellers to endemic areas.60 Educational campaigns in the
country of origin for international pilgrims would be beneﬁcial
before they arrive in the Kingdom and could be orchestrated in
close collaboration with the Hajj organizations and medical
missions from each country. This would improve compliance with
the disease prevention policies, especially among local pilgrims,
and would help early detection and seeking of medical assistance
for cases.
Emphasis should also be on regular education and training of
HCWs and professionals who may come across cases during Hajj
and Umrah. This will improve early detection and treatment of the
disease and tracing and protection of contacts to avoid spread. A
number of risk factors for death from MD are related to healthcare
delivery, including failure to recognize complications.61 Various
tools can be used to improve the recognition of serious illness,
which could be used in combination with staff training and
education, including simulation training in clinical settings.62
Emphasis on the knowledge of and adherence to published
protocols and guidelines is also key to improving outcomes in MD
and preventing secondary cases.63
4.4. Disease surveillance
Local and international surveillance of MD should, of course,
continue being an integral tool in developing and updating
preventative measures for Hajj and Umrah. The well-established
communicable diseases surveillance system in the Kingdom
should be strengthened and further supported and enhanced
during Hajj by increasing the availability of additional resources –
human, technical, and ﬁnancial. This will improve the accuracy of
reporting, early detection, and proper management of MD cases, as
well as effective data capture on the epidemiology of the disease
and the characteristics of the N. meningitidis strains involved,
including serogroups and antibiotic resistance proﬁles. Regular
analysis of such data, as well as data on the global epidemiology of
the disease, especially in countries participating in Hajj, will help
inform future policies regarding appropriate vaccination, chemo-
prophylaxis, and treatment options.
4.5. Improving compliance with preventative measures
Issues with compliance with the MD preventative strategies or
the tools used to implement these measures should be addressed.
Full coverage of vaccination and chemoprophylaxis measures
should be the aim. Strict adherence to regulations regarding
vaccination being a visa requirement for international pilgrims
would help towards this goal. Introducing an effective system to
monitor vaccinations and validate and check vaccination docu-
ments for both international and local pilgrims, as well as effectivesanctions for non-compliance, is warranted given the variable
vaccination compliance, especially among local pilgrims. Regular
and well-targeted health awareness campaigns on MD and
preventative measures should be a priority, as non-compliance
could be due to ignorance of the diseases or the regulations
regarding the preventative measures.
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